Answer
In biochemical assays, filgotinib maleate (Jyseleca) preferentially inhibited JAK1, showing more than fivefold higher potency for JAK1 than for JAK2, JAK3 and TYK2.
Sources for this answer
- Jyseleca 100 mg film-coated tabletsAlfasigma UK Limited (formerly Galapagos Biotech Limited) · emc · SmPC §5.1 Pharmacodynamic properties · Version 20Document updated
Sources checked